ArticleScientific reports2026
Development of (polyvinyl alcohol/O-carboxymethyl chitosan/PbO) nanocomposites for efficient gamma radiation protection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A polymeric blend based on polyvinyl alcohol (PVA) / carboxymethyl chitosan was developed for gamma radiation shielding applications. The nanocomposite films were fabricated using a simple solution casting method, where the readily available nanosized lead oxide PbO particles were dispersed within a polymer matrix composed of PVA, polyvinylpyrrolidone (PVP), and citric acid. The dispersion process was assisted by sonication before crosslinking, ensuring uniform distribution of oxide particles throughout the films. The physicochemical properties of the synthesized nanocomposites were systematically characterized using scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD), ultraviolet-visible spectroscopy (UV-Vis spectroscopy), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), water vapor permeability (WVP), soil burial degradation, and total soluble matter (water absorption) measurements. Gamma shielding performance was evaluated through the determination of linear and mass attenuation coefficients (μ and μ/ρ) at photon energies ranging from 59.53 to 1332 keV, using a NaI (Tl) scintillation detector with standard gamma-ray sources (Am-241, Ba-133, Eu-152, Cs-137, and Co-60). Additional shielding parameters, including half-value layer (HVL), tenth-value layer (TVL), and mean free path (MFP), were calculated. The experimental linear and mass attenuation coefficients for the blank sample, which closely matched the theoretical predictions from XCOM, verified the produced films' outstanding gamma radiation shielding capabilities. PbO nanoparticles were incorporated into the chitosan matrix to produce a uniform and compact film structure. HVL, TVL, and MFP, among other computed shielding factors, showed how well the nanocomposites attenuated gamma photons throughout a broad energy range. Furthermore, the structural stability, uniform shape, and environmental degradability of the composites were validated by physicochemical studies. These findings demonstrate that carboxymethyl chitosan/PbO nanocomposite films are attractive options for long-term radiation protection, as they combine efficient radiation-shielding capabilities with other desirable properties. While carboxymethyl chitosan/PbO nanocomposite films show promising radiation shielding efficiency, their long-term stability remains a concern, as partial material degradation may affect their sustained performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.